Erasmus MC 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   1 Trial   31 News 
  • ||||||||||  MesoPher (autologous dendritic cell vaccine) / Amphera
    Trial completion date, Trial primary completion date:  ENSURE: dENdritic Cell Therapy Combined With SURgEry in Mesothelioma (clinicaltrials.gov) -  Apr 26, 2025   
    P1,  N=16, Recruiting, 
    Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Enrollment change, Trial termination:  COVIC-19: Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (clinicaltrials.gov) -  Oct 28, 2024   
    P3,  N=120, Terminated, 
    N=680 --> 120 | Recruiting --> Terminated; Due to the significant decline in the number of newly diagnosed infections and the difficulties in opening new centers in the outgoing pandemic, recruitment declined. The Data Safety Monitoring Board recommended to stop the trial.
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal:  Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study. (Pubmed Central) -  Apr 26, 2024   
    Further randomised studies are needed of combinations of MesoPher and immune checkpoint therapy, which might increase efficacy without adding major toxicities. The results of this study may inform future intervention studies on the prophylactic and therapeutic use of antiviral antibodies in the form of ConvP or COVIg.
  • ||||||||||  MesoPher (autologous dendritic cell vaccine) / Erasmus MC, Amphera
    Trial completion, Tumor cell:  DENIM: DENdritic Cell Immunotherapy for Mesothelioma (clinicaltrials.gov) -  Feb 1, 2024   
    P2/3,  N=176, Completed, 
    The results of this study may inform future intervention studies on the prophylactic and therapeutic use of antiviral antibodies in the form of ConvP or COVIg. Recruiting --> Completed
  • ||||||||||  MesoPher (autologous dendritic cell vaccine) / Erasmus MC, Amphera, mitazalimab (ADC-1013) / Alligator Biosci
    Trial completion, Trial completion date, Trial primary completion date, IO biomarker:  MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) (clinicaltrials.gov) -  Oct 12, 2023   
    P1,  N=22, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023
  • ||||||||||  MesoPher (autologous dendritic cell vaccine) / Erasmus MC, Amphera
    Dendritic Cell Immunotherapy Versus Best Supportive Care as Maintenance Treatment in Patients with Pleural Mesothelioma (Summit 2) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_963;    
    Likely the long interval between chemotherapy and the start of treatment caused that most patients had already disease progression before or during the first 3 DC treatments, prohibiting the induction of an effective immune response. This interval was extended compared to earlier MesoPher studies because randomization and additional sterility tests.
  • ||||||||||  HBM9022 / Utrecht University, Erasmus MC, Harbour BioMed, AbbVie
    Clinical, P1 data, PK/PD data, Journal:  Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19. (Pubmed Central) -  Dec 21, 2022   
    The exploratory anti-SARS-CoV-2 activity revealed a reduction of viral load at and above the 600 mg dose of ABBV-47D11 regardless of patient demographics and baseline characteristics, however; because of the high inter-individual variability and small sample size a statistical significance was not reached. There is potential for anti-SARS-CoV-2 activity with ABBV-47D11 doses of 600 mg or higher, which could be evaluated in future clinical trials designed and powered to assess viral load reductions and clinical benefit.
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) (clinicaltrials.gov) -  Apr 1, 2022   
    P3,  N=420, Terminated, 
    N=426 --> 86 | Active, not recruiting --> Terminated; new insights into COVID19 pathogenesis N=690 --> 420 | Trial completion date: Nov 2023 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Oct 2021; vaccination uptake 80% in the target population/new COVID variant
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Journal:  Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. (Pubmed Central) -  Feb 19, 2022   
    The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested.
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Journal:  Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices. (Pubmed Central) -  Oct 20, 2021   
    TPE in COVID-19 patients may help by removing toxic cytokines, viral particles and/or by correcting coagulopathy or restoring endothelial membrane. Severity score (SOFA & APACHE II) and cytokine levels (IL-6, C-reactive protein) can be used to execute TPE therapy and to monitor response in COVID-19 patients.
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Journal:  Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. (Pubmed Central) -  Oct 20, 2021   
    The need for flexibility and adaptability remains paramount when dealing with a pandemic. As the world approaches the first anniversary of the COVID-19 pandemic with rising rates worldwide and over 115 million cases and 2·55 million deaths, respectively, it is important to reflect on how to better prepare for future pandemics as we continue to combat the current one.
  • ||||||||||  Preclinical, Journal:  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. (Pubmed Central) -  Aug 12, 2021   
    When administered after infection as therapy, higher doses of several mAb cocktails protected in vivo against viruses with a B.1.351 spike gene. Thus, many, but not all, of the antibody products with Emergency Use Authorization (EUA) should retain substantial efficacy against the prevailing SARS-CoV-2 variant strains.
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Preclinical, Journal:  SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. (Pubmed Central) -  Jun 24, 2021   
    These data highlight the importance of screening plasma donors for high levels of neutralizing antibodies. Our data show that prophylactic administration of high levels of neutralizing antibody, either monoclonal or from convalescent plasma, prevent severe SARS-CoV-2 pneumonia in a hamster model, and could be used as an alternative or complementary to other antiviral treatments for COVID-19.
  • ||||||||||  MesoPher (autologous dendritic cell vaccine) / Erasmus MC, Amphera
    Trial completion date, Trial primary completion date, Tumor cell:  DENIM: DENdritic Cell Immunotherapy for Mesothelioma (clinicaltrials.gov) -  Jan 27, 2021   
    P2/3,  N=230, Recruiting, 
    N=24 --> 54 Trial completion date: Jan 2021 --> Feb 2023 | Trial primary completion date: Jan 2021 --> Feb 2023
  • ||||||||||  Convalescent plasma therapy / Erasmus MC
    Enrollment closed, Trial completion date, Trial primary completion date:  Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (clinicaltrials.gov) -  Nov 16, 2020   
    P2/3,  N=426, Active, not recruiting, 
    Not yet recruiting --> Recruiting | N=24 --> 32 Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021